ibi351
innovent biologics
['solid tumor', 'innovent']
innovent presents clinical data of phase i study for ibi351 (kras g12c inhibitor) as monotherapy for solid tumors at the 2022 american society of clinical oncology (asco) annual meeting #stocksmarket #pressrelease
Join us at https://t.co/9QZSYoqhvl - Stock Market News and Press Releases. #StockMarket - As an affiliate, we earn from qualifying purchases.